Industry research
How to research a biotech pipeline with free public data
A step-by-step method for biotech pipeline research and due diligence using free public data: FDA approvals, ClinicalTrials.gov, SEC filings and PDUFA dates.
By the All In Biotech editorial team · Published November 18, 2026 · 6 min read
You can map most of a biotech company's clinical pipeline with free public sources: its SEC filings for what it says, ClinicalTrials.gov for the trials it has registered, Drugs@FDA for what has been approved, and announced PDUFA dates for pending FDA decisions. The method below builds a picture from each source in turn and checks them against each other.
This is a research method, not an investment view. Public data shows what has been registered, approved or disclosed. It does not tell you whether a program will succeed or what a company is worth.
The sources and what each one covers
| Source | What it shows | What it misses |
|---|---|---|
| SEC EDGAR filings | The company's own description of programs, timelines, risks and cash | Only what the company chooses or is required to disclose |
| ClinicalTrials.gov | Registered trials by phase, status, enrollment, endpoints and sites | Most preclinical work, and some ex-US or early studies |
| Drugs@FDA | Approved NDAs and BLAs, approval dates, labels and letters | Pending applications, most CBER products |
| FDA designation lists | Breakthrough and accelerated approvals | Designations granted but not yet tied to an approval |
| PDUFA dates | Announced FDA target action dates | Dates the company never announced |
No single source is complete. The value comes from comparing them.
Step 1: Read what the company says
Begin with the company's annual report (Form 10-K for US filers, Form 20-F for many foreign filers) and its most recent quarterly reports (Form 10-Q). All are free on SEC EDGAR. Look for:
- the business section's list of programs, with indication and stage for each,
- the risk factors, which often name regulatory, manufacturing and financing risks specific to each program,
- license and collaboration agreements, which show who owns which rights and where,
- the liquidity section, which states how long the company expects its cash to last.
Current reports (Form 8-K) carry material news between quarters, such as trial readouts, FDA correspondence the company chooses to disclose, or new partnerships. Company investor presentations are useful for a pipeline chart, but they are marketing documents. Treat the filings as the more careful statement.
Write down each program the company names, its stated phase and any stated timeline. This becomes the checklist for the next steps.
Step 2: Check each program against trial registrations
Most interventional trials of FDA-regulated drugs must be registered on ClinicalTrials.gov, and many sponsors also register studies run outside the US. For each program on your list, search the drug's code name and its generic name, since registrations often use the code name for early trials.
For each trial, note:
- Phase and status: recruiting, active not recruiting, completed, terminated or withdrawn. A terminated or withdrawn trial usually has a short reason in the record.
- Enrollment: anticipated versus actual. A large gap can mean a trial stopped early or grew.
- Primary completion date: the date the sponsor expects to finish collecting data for the main endpoint. Sponsors update it, so compare the current value with the record's history.
- Primary endpoint: what the trial is designed to measure. Changes to the primary endpoint over time are visible in the record history.
- Results: whether results have been posted. Registration rules require results reporting for many applicable trials, within deadlines set in the regulations.
On this site, the trial search lets you filter registered drug trials by therapeutic area, phase, sponsor and status, and the company pages group a sponsor's trials by phase. The detailed walk-through is in how to find every clinical trial for a drug.
Where the filings and the registry disagree, for example a program the company calls Phase 3 that has no Phase 3 registration, note it and look for an explanation in later filings or press releases. Registration can lag a decision, and some trials are registered under a partner's name.
Step 3: Confirm what has already been approved
Approved products tell you what the company already sells and how its prior applications went. Drugs@FDA lists each approved NDA and BLA with its approval history: the original approval, later efficacy supplements for new uses or populations, and links to approval letters and labels.
On this site, every company page lists its marketed drugs and recent approvals, and the approvals list can be filtered by year, type and FDA program flag. A few points to keep in mind:
- Drugs@FDA covers FDA's Center for Drug Evaluation and Research (CDER). Most vaccines and cell and gene therapies are approved by the Center for Biologics Evaluation and Research (CBER) and will not appear.
- Sponsor names in Drugs@FDA are written as filed. Large companies are merged across their filing names on this site, but smaller companies and subsidiaries may appear under the exact sponsor name on the application.
- An approval for a partner's product may sit under the partner's name even if your company receives royalties.
Step 4: Look at FDA program flags
FDA's expedited programs leave a public trail once a drug is approved. CDER publishes lists of approvals that used breakthrough therapy designation and accelerated approval, and Drugs@FDA marks priority review and orphan status on original approvals.
An accelerated approval in a company's history is worth noting, because the label usually depends on a confirmatory trial. On the designations page you can see breakthrough and accelerated approvals by year and by sponsor. As of November 2026, the CDER lists that feed it run through June 30, 2026, so the most recent approvals may not yet be flagged.
FDA does not publish breakthrough therapy or fast track designations for drugs still in development. Companies often announce them in filings and press releases. Orphan designations are the exception: FDA lists them in its searchable orphan designation database, including for drugs not yet approved. The programs themselves are described on FDA's expedited programs page.
Step 5: Find pending FDA decisions
When FDA accepts an application for review, it sets a target action date under the Prescription Drug User Fee Act, often called the PDUFA date. FDA does not publish these dates. Companies usually announce them in a press release or filing, and some smaller companies do not announce them at all.
This site's PDUFA calendar is compiled each week from press releases, filings, FDA's advisory committee calendar and trade press, with a link to the page that states each date. Dates move, so check the source link and the company's latest filing before relying on one. The PDUFA date explainer covers how the dates are set and why they change.
Step 6: Put it together
A simple working table keeps the research honest. One row per program, with columns for:
- program name and code name,
- indication,
- stage according to the company,
- stage according to ClinicalTrials.gov, with NCT numbers,
- next stated milestone and its source,
- any FDA date or designation, with source,
- notes on gaps or disagreements between sources.
Fill each cell from a source you can link. Leave a cell blank rather than estimate it. The gaps are often the most useful part, because they show where the public record is thin.
Limits of public pipeline data
Public sources leave out a lot, and it helps to know where:
- Preclinical programs rarely appear in registries. Only the company's own disclosures describe them.
- Ex-US trials may be registered only in other registries, such as the EU Clinical Trials Information System or WHO's international registry platform.
- Deals and rights change. A program can move to a partner, be returned or be dropped, and registries may lag.
- Results in registries are summaries. Full data appear in publications and conference presentations, and the research search on this site searches PubMed, Europe PMC and OpenAlex for published studies on a drug.
- Timing in any source is a plan, not a commitment. Primary completion dates and PDUFA dates often shift.
For a broader overview of what free tools can and cannot replace in paid databases, see free alternatives to paid pharma intelligence databases.
Frequently asked questions
- Is there a free biotech pipeline database?
- Yes. ClinicalTrials.gov, Drugs@FDA and SEC EDGAR are free, and this site combines them into company pages that list approved drugs, expedited approvals and registered trials by phase.
- What should biotech due diligence check first?
- Most analysts start with what the company says in its SEC filings, then verify each program against trial registrations and FDA records.
- Where can I find a biotech company's PDUFA date?
- FDA does not publish PDUFA dates, so they come from company press releases and filings; this site compiles announced dates in a weekly calendar with a source link for each row.
- Can public data show a company's whole pipeline?
- No. Preclinical work, many ex-US trials and undisclosed programs are not in public registries, so public data gives a partial view that should be checked against the company's own disclosures.
For information only, not medical, legal or investment advice. Facts about FDA and CMS programs are current as of the publication date; check the linked official source for changes.